• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Biodesix Named to Inc. Magazine's 2024 "Best Workplaces"

    6/18/24 8:13:00 AM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email

    Awarding Excellence in Company Culture

    Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Workplaces list. The ranking is a result of a comprehensive, data-driven measurement process to identify which American companies have excelled in creating exceptional workplaces with great company cultures.

    After collecting data from thousands of submissions, Inc. selected 543 honorees this year. Each company that was nominated took part in a comprehensive employee survey, conducted by Quantum Workplace, which included topics such as management effectiveness, perks, recognition, fostering employee growth, and overall company culture.

    Founded in 2006, Biodesix has been building on its strong science and technology foundation to intentionally cultivate a high-performing, mission-driven company culture. The company logo includes a green thumb print insignia, morphed from the imagery of biomarkers and DNA strands. The logo is a daily reminder to Biodesix teammates that they have the ‘green light' to put their fingerprints on all innovations and processes at the company.

    During this era of sustained, high double-digit growth in revenues and controlled team growth, Biodesix strives to preserve and cultivate its unique culture. The Biodesix Leadership Team believes it provides an advantage for attracting the best talent, thus accelerating the ability to fulfill the Biodesix mission and assist more healthcare professionals and their patients.

    The Best Workplaces employee survey resulted in a 93% (highly) engaged employee score for Biodesix, and "collaborative" was the descriptor most-used by team members to describe the workplace. This is a powerful performance benchmark as Biodesix views engaged teammates as the catalysts to transform an industry or a company. In the fight against cancer and with the need to accelerate precision medicine, this is exactly the kind of teammate that patients, healthcare professionals, and biopharma partners rely upon.

    "It's an honor for us to be recognized by Inc. as a Best Workplace because we are committed to a culture of excellence," said Scott Hutton, CEO of Biodesix. "This award is truly a reflection of our amazing team, and we are very proud of each of our team members - their commitment, their collaborative approach, their impact in cancer care and in the broader healthcare ecosystem."

    "Each year, Inc.'s Best Workplaces program recognizes the very best in terms of companies that have fostered a truly amazing culture," says Inc. editor-in-chief Mike Hofman. "We use hard metrics and data as well as qualitative measures for judging in order to find the very best—and we're proud that the program is highly selective."

    About Biodesix

    Biodesix is a leading diagnostic solutions and services company with a focus in lung disease. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting the time to treatment. Biodesix collaborates with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information, visit biodesix.com.

    About Inc. Media

    The world's most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit www.inc.com.

    About Quantum Workplace

    Quantum Workplace, based in Omaha, Nebraska, is an HR technology company that serves organizations through employee-engagement surveys, action-planning tools, exit surveys, peer-to-peer recognition, performance evaluations, goal tracking, and leadership assessment. For more information, visit www.QuantumWorkplace.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240618129059/en/

    Get the next $BDSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Pestano Gary Anthony converted options into 1,481 shares and sold $5,445 worth of shares (540 units at $10.08), increasing direct ownership by 11% to 9,387 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Commercial Officer O'Kane Kieran converted options into 1,600 shares and sold $5,889 worth of shares (584 units at $10.08), increasing direct ownership by 13% to 8,885 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    CFO, Sec'y & Treasurer Cowie Robin Harper sold $9,489 worth of shares (941 units at $10.08) and converted options into 2,584 shares, increasing direct ownership by 12% to 15,297 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:21 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $903,561 worth of shares (82,465 units at $10.96) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/26/26 9:28:57 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $999,997 worth of shares (142,045 units at $7.04) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/23/25 9:29:04 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    SEC Filings

    View All

    SEC Form S-8 filed by Biodesix Inc.

    S-8 - BIODESIX INC (0001439725) (Filer)

    2/6/26 4:14:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Biodesix Inc.

    SCHEDULE 13D/A - BIODESIX INC (0001439725) (Subject)

    1/27/26 2:28:12 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Biodesix Inc.

    SCHEDULE 13G - BIODESIX INC (0001439725) (Subject)

    1/26/26 1:59:41 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately t

    2/12/26 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

    Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX) (the company), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). The financial results included in this release pertaining to the fourth quarter and fiscal 2025 are preliminary, unaudited, and subject to final review and adjustment. "Biodesix finished 2025 with a strong fourth quarter delivering

    1/12/26 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

    Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings. At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago

    12/3/25 8:22:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix downgraded by William Blair

    William Blair downgraded Biodesix from Outperform to Mkt Perform

    5/14/25 8:54:25 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Biodesix

    Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

    9/16/24 8:45:16 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Biodesix with a new price target

    Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

    7/26/24 7:48:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

    12/16/22 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

    12/8/21 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

    SC 13G/A - BIODESIX INC (0001439725) (Subject)

    11/13/24 7:30:22 AM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Biodesix Inc.

    SC 13G - BIODESIX INC (0001439725) (Subject)

    6/24/24 12:16:38 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

    SC 13D/A - BIODESIX INC (0001439725) (Subject)

    5/23/24 7:10:37 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately t

    2/12/26 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Third Quarter 2025 Results and Highlights

    Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. "We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year," said Scott Hutton, Chief Exe

    11/3/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

    LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2025 after the close of trading on Monday, November 3. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours aft

    10/20/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care